The Quantellect read.As of Nov 19, 2026, 12 active firms cover Tyra Biosciences Inc: 11 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $29.00 to $59.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $48.20 sits 145% above the current $19.65. The rating mix has stayed broadly stable, with Buy-side ratings easing from 12 to 11 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.64 next quarter toward $-2.96 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 active firms
Buy
Strong Buy00%
Buy1192%
Neutral18%
Sell00%
Strong Sell00%
Based on 12 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$48.20
+145.3% upside
Average target across 10 active firms as of Nov 19, 2026 vs $19.65 current
Highest Target$59.00
Average Target$48.20
Lowest Target$29.00
Detailed analyst forecasts for TYRA
Showing 1–13 of 13 named analysts shown · 12 active firms in the rating projection
As of Nov 19, 2026, 11 of 12 active firms rate TYRA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TYRA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.64
Range $-0.80 – $-0.51 · 5 analysts · -1% YoY
Next period, 5 analysts expect Tyra Biosciences Inc to earn $-0.64 a share (range $-0.80 – $-0.51), versus $-0.64 a year earlier. Full-year consensus is $-2.75, growing to $-2.96 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Tyra Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TYRA.
#1
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Buy
$29.00+47.6% to target
Overall win rate
33%
+ Follow
#2
Li Watsek
Cantor Fitzgerald · Rank #357
Buy
No targeton TYRA
Overall win rate
38%
+ Follow
#3
Robert Driscoll
Wedbush · Rank #490
Buy
$53.00+169.7% to target
Overall win rate
32%
+ Follow
#4
John Newman
Canaccord Genuity · Rank #538
Buy
$50.00+154.5% to target
Overall win rate
31%
+ Follow
#5
Allison Bratzel
Piper Sandler
Buy
$56.00+185.0% to target
Coverage
—
+ Follow
TYRA stock forecast FAQ
What is TYRA's average 12-month price target?+
The 10 active firms with a live target average $48.20 for Tyra Biosciences Inc over the next 12 months, ranging from a $59.00 high to a $29.00 low, as of Nov 19, 2026.
Is TYRA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 12 active firms as of Nov 19, 2026, 11 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TYRA?+
The Street-high target is $59.00 (Barclays), and the Street-low is $29.00 (HC Wainwright & Co.). The average of all 10 active-firm targets is $48.20.
How many active Wall Street firms cover TYRA?+
12 active firms have a recognized rating on Tyra Biosciences Inc as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TYRA?+
Among analysts who currently cover TYRA, Mitchell Kapoor of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #305). Their current call is Buy with a $29.00 target.
What is Tyra Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.64 per share (range $-0.80 – $-0.51) across 5 analysts. Full-year EPS is projected at $-2.75, rising to $-2.96 the following year.
How much revenue is Tyra Biosciences Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading TYRA lately?+
As of Nov 19, 2026, 11 of 12 active firms rate TYRA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TYRA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.